Researchers offer new model for uncovering true HIV mortality rates in ZambiaJanuary 12, 2018
WASHINGTON -- A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.
Survival represents the most important indicator of successful HIV treatment, according to the researchers. According to UNAIDS, AIDS-related deaths have fallen by 50 percent since 2005--largely due to the successes of national HIV programs with support from PEPFAR and the Global Fund. Yet, because routine monitoring and evaluation fails to systematically capture most deaths, it can be challenging to accurately assess the impact of HIV services and to identify where improvement is most needed, the researchers say.
The Better Information for Health in Zambia ("BetterInfo") study begins to examine HIV survival rates in Zambia. Published January 12 in PLOS Medicine, the work was conducted by a team of researchers co-led by Charles Holmes, MD, MPH, faculty co-director of Georgetown University Medical Center'sCenter for Global Health and Quality, and visiting associate professor at Georgetown's School of Medicine. Holmes led the work along with Izukanji Sikazwe, MBChB, MPH, chief executive officer of the Centre for Infectious Research in Zambia (CIDRZ) and Elvin Geng, MD, MPH, of the University of California, San Francisco. Holmes, who previously led CIDRZ, also serves as associate professor of international health at the Johns Hopkins University Bloomberg School of Public Health and associate professor of medicine at the Johns Hopkins University School of Medicine.
The research was conducted in Zambia through a partnership with CIDRZ and the Zambian Ministry of Health, in close collaboration with numerous local and global academic centers and researchers.
The research group set out to provide a more accurate representation of site- and regional-level mortality among people on HIV therapy in Zambia by characterizing the extent of under-reporting of mortality and the variability in data collection and use, and to assess the broader impact this might have on treatment programs and outcomes.
The group applied a multistage sampling-based approach--which they say is a novel methodology in this context--to obtain regionally representative mortality estimates in four Zambian provinces (Lusaka, Southern, Eastern, and Western). The estimates were also sufficiently precise to quantify variation in death rates among clinic sites.
They looked at a sample population of more than 160,000 patients who had visited government-operated HIV treatment sites in these provinces to determine: the magnitude of deaths of those who were taking antiretroviral therapy (ART); when deaths occurred; which groups are at highest risk of death; and whether these factors differ by region, facility, or other variables.
They also traced patients who were lost to follow-up to ascertain their status, and then used this information to create a corrected regional survival estimate as well as corrected site-specific mortality estimates.
The BetterInfo study concluded that mortality is substantially underreported in routine provincial program data--by as much as three- to nine-fold--among HIV-infected individuals starting ART, leading to a change in the ranking of provinces by mortality rates.
At the site-level, "corrected" mortality rates were found to be up to 23-fold higher among those on ART. The study also found unexpectedly high variability from site to site in reported mortality rates, ranging from less than 1 death per 100 person-years to up to 13.4 deaths per 100 person years over a two-year period.
"Even as we strive to reduce new HIV infections and end the HIV pandemic as a public health threat, we must not lose sight of premature deaths occurring amongst people living with HIV who are on treatment," Holmes says. "HIV treatment is not a 'set it and forget it' proposition--deaths often occur outside of the health system and are therefore 'silent' events that are unknown to those providing or managing care.
"We believe our scalable approach, which builds on and extends earlier sampling methods, provides actionable data to clinic, provincial and national decision-makers to ensure the HIV program in Zambia is able to become more patient-centered and impactful," he says.
Based on the findings, certain prevailing assumptions that underlie HIV programs may need to be reexamined. For example, the researchers say it has been assumed that most patients on treatment for longer periods of time will be more stable than those just starting treatment. However, the study data suggest that time on therapy alone may not be a reliable marker of stability, a finding that will have implications for delivery strategies recommending less health system interaction for patients considered clinically stable.
In addition, approximately 50 percent of deaths among those newly starting ART occurred relatively shortly after a recent clinic visit, suggesting even greater need for attention to diagnostic services and clinical vigilance for potential co-existing illnesses.
Overall, the authors seek to encourage national- and global-level policy makers to investigate and address the root causes of underestimated and highly variable mortality rates so they can refocus their quality improvement efforts and strengthen HIV programs.
"These data from the BetterInfo study have provided new targets for quality improvement efforts, and we look forward to further evidence as it emerges that will enable us to support the strongest possible national HIV program in Zambia," says CIDRZ's Sikazwe. "We recommend that others consider the application of similar large-scale surveillance methodologies in order to better understand their program outcomes, and we are excited to facilitate broader adoption through the forthcoming release of a "BetterInfo" toolkit and other materials."
Holmes adds, "We believe our study also highlights the critical need for investments in vital status registries and data systems to enable better visibility into patient outcomes. These investments are critical not just for the HIV response, but for broader efforts to combat chronic conditions such non-communicable diseases and achieve universal health coverage."
"Estimated mortality on HIV treatment among active patients and patients lost to follow-up in 4 provinces of Zambia: Findings from a multistage sampling-based survey." https://doi.org/10.1371/journal.pmed.1002489
About Georgetown University Medical Center
Georgetown University Medical Center (GUMC) is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health. Connect with GUMC on Facebook, Twitter (@gumedcenter). Connect with Georgetown University School of Medicine on Facebook (Facebook.com/somgeorgetown), Twitter (gumedicine) and Instagram (@GeorgetownMedicine).
Georgetown University Medical Center
Related Hiv Articles:
A new study finds defective HIV proviruses, long thought to be harmless, produce viral proteins and distract the immune system from killing intact proviruses needed to reduce the HIV reservoir and cure HIV.
Almost 30,000 newly diagnosed HIV infections were reported by the 31 European Union and European Economic Area (EU/EEA) countries in 2015, according to data published today by ECDC and the WHO Regional Office for Europe.
A new study led by researchers at Massachusetts General Hospital finds that cigarette smoking substantially reduces the lifespan of people living with HIV in the US, potentially even more than HIV itself.
HIV-positive individuals who smoke cigarettes may be more likely to die from smoking-related disease than the infection itself, according to a new study published in the Journal of Infectious Diseases.
An estimated 1.2 million people live with HIV in the United States, with nearly 13 percent being unaware of their infection.
A major new analysis from the Global Burden of Disease 2015 study, published today in The Lancet HIV journal, reveals that although deaths from HIV/AIDS have been steadily declining from a peak in 2005, 2.5 million people worldwide became newly infected with HIV in 2015, a number that hasn't changed substantially in the past 10 years.
Investigators from the National Institutes of Health have discovered that cells from HIV-infected people whose virus is suppressed with treatment harbor defective HIV DNA that can nevertheless be transcribed into a template for producing HIV-related proteins.
Among nearly 900 serodifferent (one partner is HIV-positive, one is HIV-negative) heterosexual and men who have sex with men couples in which the HIV-positive partner was using suppressive antiretroviral therapy and who reported condomless sex, during a median follow-up of 1.3 years per couple, there were no documented cases of within-couple HIV transmission, according to a study appearing in the July 12 issue of JAMA, an HIV/AIDS theme issue.
Researchers from UAB, Emory and Microsoft demonstrate that HIV has evolved to be pre-adapted to the immune response, worsening clinical outcomes in newly infected patients.
Actor Charlie Sheen's public disclosure in November 2015 that he has the human immunodeficiency virus (HIV) corresponded with the greatest number of HIV-related Google searches ever recorded in the United States, according to an article published online by JAMA Internal Medicine.
Related Hiv Reading:
HIV Essentials 2017
by Paul E. Sax (Author), Calvin J. Cohen (Author), Daniel R. Kuritzkes (Author)
The world's leading experts provide all the 'essentials' needed to manage HIV patients in the office, on the ward, and in the ICU.
Completely revised and updated, HIV Essentials 2017 incorporates the latest clinical guidelines into a step-by-step guide to the diagnosis, evaluation, management, and prevention of HIV infection and its complications. Topics include: opportunistic infections and other HIV complications, treatment of HIV and pregnancy, antiretroviral drug summaries, post-exposure prophylaxis, as well as commercially available dosage forms for all ARVs. View Details
Fundamentals of HIV Medicine: (CME edition)
by American Academy of HIV Medicine (Compiler), W. David Hardy (Compiler)
Completely updated for 2017, Fundamentals of HIV Medicine is a comprehensive clinical care publication for the treatment of HIV/AIDS. Published by the American Academy of HIV Medicine, the book offers physicians, pharmacists, nurse practitioners, and other care providers the most up-to-date overview of the latest HIV treatments and guidelines plus online access to CME. The online access expires August 2018.
Embodying the AAHIVM's commitment to promoting uniform excellence in care of seropositive patients, Fundamentals of HIV Medicine 2017 empowers health... View Details
2018 ADULT HIV/AIDS TREATMENT POCKET GUIDE (2018 edition)
by John G Bartlett (Author), Paul A Pham (Author)
This HIV/AIDS summarizes National Clinical Guidelines with an attempt to achieve brevity, clarity and accuracy in guiding clinical decisions relevant to the management of adult patients with HIV/AIDS. This guide includes expanded drug-drug interactions tables, antiretroviral pictures tables, and summary of treatment guidelines.View Details
100 Questions & Answers About HIV and AIDS
by Joel E. Gallant (Author)
Whether you're a newly diagnosed patient or a friend or relative of someone suffering from HIV or AIDS, this book can help. Offering both doctor and patient perspectives, 100 Questions & Answers About HIV and AIDS, Fourth Edition provides authoritative and practical answers to the most commonly asked questions by patients and their loved ones. What is the difference between HIV and AIDS? How can HIV infection be prevented? How do I find the right medical care?
Along with the answers to these and other questions, this book provides information on diagnosis, treatment, living with HIV... View Details
Taking Turns: Stories from HIV/AIDS Care Unit 371 (Graphic Medicine)
by MK Czerwiec (Author)
In 1994, at the height of the AIDS epidemic in the United States, MK Czerwiec took her first nursing job, at Illinois Masonic Medical Center in Chicago, as part of the caregiving staff of HIV/AIDS Care Unit 371. Taking Turns pulls back the curtain on life in the ward.
A shining example of excellence in the treatment and care of patients, Unit 371 was a community for thousands of patients and families affected by HIV and AIDS and the people who cared for them. This graphic novel combines Czerwiec’s memories with the oral histories of patients, family members, and staff. It... View Details
Living a Healthy Life with HIV
by Allison Webel RN Ph.D (Author), Kate Lorig DrPH (Author), Diana Laurent MPH (Author), Virginia González MPH (Author), Allen L. Gifford MD (Author), David Sobel MD MPH (Author), Marian Minor PT PhD (Author)
Completely updated to the current care guidelines from the Centers for Disease Control and elsewhere, this book addresses the current emphasis on managing medications for HIV treatment and many of the illnesses that commonly occur along with HIV. Combining the latest medical advice with the ideas of hundreds of people living with HIV, the book is helpful for adults living with HIV, and for friends, family members, and others who support anyone struggling with HIV. New additions to this edition include topics such as aging with HIV and coping with the emotions brought about by being a... View Details
HIV Pharmacotherapy: The Pharmacist's Role in Care & Treatment
by Jason J. Schafer (Author), Jennifer Cocohoba (Author), Elizabeth Sherman (Author), Alice Tseng (Author)
Pharmacists now have a new resource to help expand their HIV knowledge, guide their treatment, and provide comprehensive care. This book is the first of its kind to provide pharmacists with a consolidated resource for offering care to patients with HIV infection, including diagnosis, primary care, pharmacological management of co-infections, and more. This resource will help prepare pharmacists to take a lead role in the care and treatment of patients with HIV, and will be a valuable guide for students, residents, and clinical pharmacists to build expertise in tailoring antiretroviral... View Details
HIV & AIDS: A Very Short Introduction (Very Short Introductions)
by Alan Whiteside (Author)
In 2008 it was believed that HIV/AIDS was without doubt the worst epidemic to hit humankind since the Black Death. The first case was identified in 1981; by 2004 it was estimated that about 40 million people were living with the disease, and about 20 million had died. Yet the outlook today is a little brighter. Although HIV/ AIDS continues to be a pressing public health issue the epidemic has stabilised globally, and it has become evident it is not, nor will it be, a global issue. The worst affected regions are southern and eastern Africa. Elsewhere, HIV is found in specific, usually,... View Details
Sanford Guide to HIV/AIDS Therapy 2017
by Michael S., M.D. Saag (Editor), Andrew T., M.D. Pavia (Editor), Henry F., M.D. Chambers (Editor), George M., M.D. Eliopoulos (Editor), David N., M.D. Gilbert (Editor)
HIV: Challenges and Concerns
by Chris Stinson (Editor)
HIV and AIDS are diseases that currently have no cure. Therapies that slow down the effects of the disease as well as its progression into AIDS are proving to be very successful. Drugs that can combat HIV viruses are collectively called antiretroviral therapies. These can reduce the multiplication of the virus by blocking its mutation. The concept of “treatment as prevention” has also become a recommended practice to reduce cross-infection. The topics covered in this book offer the readers new insights in this field. It is a vital tool for all researching or studying HIV treatment and... View Details